Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With 131I-Refractory Differentiated Thyroid Cancer(ALTER01032)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Acronyms ALTER01032
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 18 Aug 2023 Results (n=37)published in the Clinical Cancer Research
- 21 Sep 2020 Status changed from active, no longer recruiting to completed.
- 21 Sep 2020 Primary endpoint (Progression-free Survival (PFS)) has been met.